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Collaboration between academics and industry in clinical trials: 
cross sectional study of publications and survey of lead  
academic authors
Kristine Rasmussen,1 Lisa Bero,2 Rita Redberg,3 Peter C Gøtzsche,1 Andreas Lundh4
ABSTRACT
Objectives
To determine the role of academic authors, funders, 
and contract research organisations in industry 
funded trials of vaccines, drugs, and devices and to 
determine lead academic authors’ experiences with 
industry funder collaborations.
Design
Cross sectional analysis of trial publications and 
survey of lead academic authors.
eligibility criteria fOr selecting stuDies
The most recent 200 phase III and IV trials of vaccines, 
drugs, and devices with full industry funding, at least 
one academic author, published in one of the top 
seven high impact general medical journals (New 
England Journal of Medicine, Lancet, JAMA, BMJ, 
Annals of Internal Medicine, JAMA Internal Medicine, 
and PLoS Medicine).
results
Employees of industry funders co-authored 173 
(87%) of publications; 183 (92%) trials reported 
involvement of funders in design, and 167 (84%) 
reported involvement of academic authors. Data 
analysis involved the funder in 146 (73%) trials and 
the academic authors in 79 (40%). Trial reporting 
involved the funder in 173 (87%) trials and 
academic authors in 197 (99%). Contract research 
organisations were involved in the reporting of 123 
(62%) trials.
Eighty (40%) of 200 lead academic authors 
responded to the survey. Twenty nine (33%) of 
the 80 responders reported that academics had 
final say on the design. Ten responders described 
involvement of an unnamed funder and/or contract 
research organisation employee in the data analysis 
and/or reporting. Most academic authors found 
the collaboration with industry funder beneficial, 
but 3 (4%) experienced delay in publication 
due to the industry funder and 9 (11%) reported 
disagreements with the industry funder, mostly 
concerning trial design and reporting.
cOnclusiOns
Industry employees and academic authors are 
involved in the design, conduct, and reporting of 
most industry funded trials in high impact journals. 
However, data analysis is often conducted without 
academic involvement. Academics view the 
collaboration as beneficial, but some report loss of 
academic freedom.
Introduction
Collaboration between industry and academics is 
common in the development of vaccines, drugs, and 
devices, as it can be mutually beneficial. The academics 
provide access to trial participants and clinical and 
methodological expertise, and industry provides 
funding and expertise. The degree of independence 
and the roles of academics and industry vary across 
trials. Trials may be run by academic trial units 
independently but with unrestricted industry funding, 
or the only contribution from industry could be free 
provision of study drugs.10 Alternatively, academics 
may be involved in trials as honorary authors to give a 
trial scientific credibility and downplay the role of the 
industry funder.3 4
Previous work and examples suggest that 
collaboration between academics and industry may 
result in commercial considerations outweighing 
science and constraints on academic freedom. For 
example, previous studies have found that some trial 
agreements permit funders to block publication.5-8 
Furthermore, academics have reported problems with 
stalling of publications, restriction of publication 
rights, and threats to never fund their institution again 
owing to reporting of negative results or harms.9 A 
survey of Canadian trial investigators found problems 
in relation to industry control over study design, 
ownership of and access to data, and data analysis.10
Although most clinical drug and device trials are 
funded by industry, the nature of the collaboration 
between industry and academics has received little 
attention.11 Previous studies have considered the 
question on a general level.5-10  12 To our knowledge, 
no studies have surveyed the role and practices of 
academics, industry, and contract research organisations 
(CROs) when collaborating in relation to specific clinical 
trials of vaccines, drugs, or devices. Our objectives were 
to determine the role of academic authors, funders, 
and CROs in industry funded trials of vaccines, drugs, 
and devices and to determine lead academic authors’ 
experiences with industry funder collaborations.
WhAT IS AlReAdy knoWn on ThIS TopIC
The biomedical industry funds most clinical trials
Industry funders may influence how trials are designed and reported, sometimes 
serving financial rather than public interest
WhAT ThIS STudy AddS
In most industry funded trials reported in high impact medical journals, all 
aspects of the clinical trial were influenced by the industry funder
Reported access to data does not always mean access to the entire trial dataset
Lead academic authors involved in industry funded trials found the collaboration 
with the funder beneficial, but some reported loss of academic freedom
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Methods
This study was in two parts and was based on a 
protocol written before the conduct of the study. The 
first part of the study was a cross sectional study of 
trial publications, and the second part was a survey 
of the lead academic authors of the 200 most recent 
industry funded trials of vaccines, drugs, and devices 
published in the top seven high impact general medical 
journals. We started with descriptive and quantitative 
data collection from trial publications and built on 
that with a survey of lead academic authors. We used 
the responses from the survey to further explore and 
explain the results from the trial publications.
cross sectional study
Search
One author (KR) manually searched the top seven 
general and internal medical journals according to the 
impact factor of the 2015 Journal Citation Report (the 
New England Journal of Medicine (NEJM), the Lancet, 
JAMA, the BMJ, the Annals of Internal Medicine, 
JAMA Internal Medicine, and PLoS Medicine) for the 
most recent trial publications meeting our inclusion 
criteria.13 The search started from April 2017 and went 
backwards in time until 200 studies were included.
Inclusion criteria
We included publications of phase III and IV trials 
with one or more academic authors (determined using 
the institutional address) that disclosed full industry 
funding. We defined full industry funding as any trial 
with funding exclusively from one or more vaccine, 
pharmaceutical, or device companies. We included 
industry supported trials described as investigator 
initiated if the only funding was from industry 
sources.14
We defined academic authors as authors whose 
affiliation in the publication was a clinic, hospital, 
university, or non-profit academic research centre. We 
selected the lead academic author according to the 
following rank: corresponding author, first author, last 
author, second author, third author, etc. If a publication 
had more than one academic corresponding author, 
we deemed the lead academic author according to the 
following rank: first author, last author, second author, 
third author, etc.
Exclusion criteria
We excluded trials of fluid therapy and dietary 
supplements, trials with mixed funding (public and 
industry funded, including free provision of study 
drug or device only), and secondary publications (for 
example, subgroup analysis). If two publications of 
the same trials were identified (for example, an interim 
analysis and the planned analysis), we included 
only the most recent publication. If a lead academic 
author had published more than one eligible trial, we 
included only the most recent trial. A second author 
(AL) confirmed that the 200 trial publications met the 
inclusion and exclusion criteria. Disagreements were 
resolved by discussion.
Data extraction
For each trial publication, two authors (AL, KR) 
independently extracted data into a standardised data 
sheet. We extracted data on the role of the academic 
authors, funder, and CRO with regard to trial design, 
conduct, data analysis, and reporting. Academic 
authors were all employed by clinics, hospitals, and/
or universities. We defined a funder employee as an 
author or acknowledged person who had the funding 
company listed as affiliation and a CRO employee as 
an author or acknowledged person who had a CRO 
listed as affiliation. We defined a CRO as a commercial 
company that provides research services to the funder 
in relation to certain parts of the trial design, conduct, 
analysis, or reporting. This definition included people 
who were hired by the funder as statistical consultants 
or medical writers.
We also extracted data from the publications 
on access to data, trial agreements, and the lead 
academic author’s conflicts of interest as disclosed in 
the included paper. If the publication did not report 
conflicts of interest, we retrieved information from the 
International Committee of Medical Journal Editors 
(ICMJE) disclosure form. We focused on conflicts of 
interest outside the submitted work, as most lead 
academic authors were investigators and we wanted 
to identify the group of academic authors with more 
extensive funder collaboration. Therefore, we did not 
count being an investigator or receiving a grant from 
the trial funder in relation to the included trial as a 
conflict of interest (see appendix 1 for full details 
of the fields extracted). In this study, we used the 
ICMJE definition of a conflict of interest: “A conflict of 
interest exists when professional judgment concerning 
a primary interest (such as patients’ welfare or the 
validity of research) may be influenced by a secondary 
interest (such as financial gain).”15 Disagreements 
were resolved by discussion.
When we started the data extraction, we found that 
the contribution of individual authors and role of the 
funder were often not clear from the publications 
in the NEJM, as roles were typically described in 
broad terms (for example, the trial was designed 
by a steering committee of academics and funder 
representatives, but the publication did not describe 
which authors were members). We therefore decided 
to include supplementary material (such as lists 
of steering committee members and contributions 
statements) for data extraction of NEJM publications, 
if available.
survey
We designed our survey by using Qualtrics (www.
qualtrics.com). Each lead academic author was tracked 
by a unique identifier to allow matching of the survey 
response to the publication and to track authors who 
had not responded. The identity of survey authors was 
available to only two of the authors of our study (AL 
and KR), and we did not link any quotes to individual 
identifiers, so the rest of the authors and the public 
could not match responses with specific authors.
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Survey questions were designed, ordered, and sent 
out in a fashion recommended for increasing the 
response rate and the reliability of the responses.16 17 
The survey included 20 questions with possible 
answers in tick boxes and the possibility of writing a 
more detailed comment. The questions covered design, 
analysis, and reporting of the trial, data access, trial 
agreements, and experience with the collaboration 
(appendix 2). We pilot tested the survey on seven 
academics identified from our network who had 
previously collaborated with industry and modified 
the survey slightly according to their advice.
We emailed the survey to the 200 lead academic 
authors in June 2017, and reminders were emailed 
twice monthly until the end of September 2017 (seven 
reminder emails). Thereafter, we contacted non-
responders by letter in October 2017 and by phone in 
November 2017.
If a survey response had a discrepancy between what 
was answered in the available tick boxes and what was 
described in additional comments, we reclassified the 
tick box answer after discussion between two authors 
(AL, KR). For example, in response to the question 
on involvement in statistical analysis, the academic 
author had ticked only “funder” whereas the comments 
clearly described that the academic authors were also 
involved. This led to reclassification of responses for 16 
responders, with two having two responses changed 
and one having three responses changed.
Data analysis
We used only descriptive statistics. We reported 
responders’ comments in a collated fashion where 
possible. We reported discrepancies between survey 
and trial publication. For characteristics of trials, we 
also stratified characteristics by vaccine, drug, and 
device trials and survey response type (responders, 
declined via email, accessed survey but did not 
respond, and non-responders). For the survey, we 
stratified responses by vaccine, drug, and device trials. 
We also stratified survey responders into those still 
collaborating with the funder or who would collaborate 
in the future and those no longer collaborating with 
the funder to assess whether these had important 
differences.
For both trial characteristics and survey responses, 
we stratified results into groups of independent trials 
and industry trials on the basis of the publications, 
as we hypothesised that these groups would differ. 
We classified industry funded trials as independent 
industry funded trials if neither the funder nor a 
CRO was involved in any part of the design, conduct, 
analysis, or reporting of the trial. To assess the effect of 
conflicts of interest in relation to two survey questions 
on “funder problems,” we stratified responses by lead 
academic authors with conflicts of interest related to 
the funder and lead academic authors without conflicts 
of interest.
Results
cross sectional study
We identified 1139 publications and included 200 
trials published between July 2014 and April 2017 
(fig 1). We included trials from all selected journals 
except PLoS Medicine, for which no trials met our 
inclusion criteria because none were fully industry 
funded.
Trial characteristics
All but seven trials were published in the NEJM (53%), 
the Lancet (31%), and JAMA (13%), and 165 (83%) 
trials were drug trials (see table 1 and appendix 7 for 
stratified analyses). The median number of authors 
was 19 (range 5-103), with one trial published in 
JAMA having a study group listed as authors, which 
consisted of 103 people. In 173 (87%) of the trials, one 
or more co-authors were employees of the funder. The 
corresponding author was an academic author in 192 
(96%) trials. The lead academic author had conflicts of 
interest with the trial funder in 165 (83%) trials.
Involvement of funder, academic authors, and CROs 
as reported in trial publications
In most trials, both funder and academic authors were 
involved in the design, conduct, and reporting (fig 2). 
In all, 183 (92%) trials reported funder involvement in 
design and 167 (84%) academic author involvement. 
Trial reporting involved the funder in 173 (87%) trials 
and academic authors in 197 (99%); contract research 
organisations were involved in the reporting of 123 
(62%) trials. In contrast, data analysis was done by 
the funder and/or a CRO without the involvement of 
academic authors in around half of trials. Data analysis 
involved the funder in 146 (73%) trials and the 
academic authors in 79 (40%). Only 8 (4%) trials were 
Trials included (n=200)
Excluded (n=939):
  Non-industry funded (n=621)
  Mixed funding (n=202)
  Not a phase III or IV trial (n=71)
  Trials by lead academic authors already included (n=19)
  Secondary analysis (n=16)
  Non-drug, device, or vaccine intervention (n=8)
  More recent publication of study included (n=2)
Trials identied (n=1139):
  New England Journal of Medicine (n=373)
  The Lancet (n=313)
  JAMA (n=211)
  Annals of Internal Medicine (n=57)
Lead academic authors contacted (n=200):
  Unresponsive (n=94, 47%):
    Unreachable based on contact information in publication and additional searching (n=3)
    Did not respond despite email, postal, and phone reminders (n=91)
  Responded (n=106, 53%):
    Responded to survey* (n=80):
      Completed survey (n=73)
      Provided responses to some of the survey questions (n=7)
    Accessed survey, without providing any responses despite email, postal, and phone reminders
      (n=10)
    Replied that they did not want to participate (n=16)
  JAMA Internal Medicine (n=74)
  The BMJ (n=61)
  PLoS Medicine (n=50)
fig 1| study flow diagram. *response was included by one author who later replied that 
he did not have time to complete survey
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classified as independent trials (that is, all aspects of 
the industry funded trial were carried out by academic 
authors without involvement of the funder or a CRO). 
In four of these eight trials, the lead academic author 
had disclosed conflicts of interest with the funder that 
were outside the submitted work.
The data analysis was done by a median of 3 (range 
1-31) authors with the involvement of a median of 1 
(0-11) funder employee. In 95 trial publications, we 
were unable to identify the exact number of authors 
involved in data analysis. Although we aimed to extract 
data on who did the actual statistical analysis, this 
was often difficult as publications used phrases such 
as “All authors analysed and interpreted the data,” 
even though a publication might have 18 authors. 
Other publications used a phrase from the ICMJE 
requirements for authorship, describing individual 
authors’ involvement in “acquisition, analysis, or 
interpretation of data,” and thus grouped three very 
different processes making it impossible to assess who 
did the statistical analysis.15 In 10 trials, the funder 
was stated as having no role in the data analysis, but 
who else was involved was unclear (for example, a 
CRO).
Data access and trial agreements
All authors declared access to data in 77 (39%) trials, 
and some academic authors did so in an additional 67 
(34%) trials. For the remaining trials, 52 (26%) stated 
that authors vouched for the data without specifying 
who had access and 4 (2%) had no description of data 
access. Only 9 (6%) of 144 trials reporting data access 
specified the type of data: 2 (1%) reported access 
to raw data, 3 (2%) access to analysed data only, 1 
(1%) access to summary data for all patients, but only 
individual patient data from own institution, and 3 
(2%) access to data used in the publication.
In 16 (8%) trial publications, confidentiality 
agreements with the funder were described, 
and 4 (2%) publications described that no such 
agreements existed. For the remaining 180 (90%) 
trials, the publication did not mention confidentiality 
agreements.
survey
We received responses from 106 (53%) lead academic 
authors (fig 1). Three lead academic authors were 
unreachable by email, post, and telephone. Eighty 
(40%) of 200 responded to survey questions, 10 (5%) 
accessed the survey without providing any response, 
and 16 (8%) replied that they did not want to 
participate (appendix 3). Our comparison of trials’ and 
authors’ characteristics between those who responded 
to those who did not showed no important differences 
(appendix 4).
Decisions on and involvement in trial design, 
analysis, and reporting, as reported by lead 
academic authors
Academic authors were involved in the choice of 
comparator treatment in most trials, whereas funders 
were involved in choice of outcomes in most trials 
(appendix 5). Twenty nine (33%) of responders 
reported that academics had final say on the design. 
See figure 3 for all responses, box 1 for selected 
authors’ comments, and appendix 6 for additional 
authors’ comments.
table 1 | characteristics of 200 industry funded trials
no (%)
journal
New England Journal of Medicine 106 (53)
Lancet 62 (31)
JAMA 25 (13)
Annals of Internal Medicine 4 (2)
JAMA Internal Medicine 2 (1)
BMJ 1 (1)
intervention
Drug 165 (83)
Device 26 (13)
Vaccine 9 (5)
comparator
Active treatment 79 (40)
Multiple arms (active treatment and placebo) 27 (14)
Placebo or no additional treatment 94 (47)
authorship
Academic and industry funder authors* 173 (87)
Academic and CRO authors 5 (3)
Solely academic authors 22 (11)
First author academic 196 (98)
First author funder 4 (2)
Last author academic 154 (77)
Last author funder 42 (21)
Last author CRO 2 (1)
Last author other† 2 (1)
Corresponding author academic 192 (96)
Corresponding author funder 8 (4)
lead academic author’s reported conflicts of interest
Conflict(s) of interest with funder‡ 165 (83)
Conflict(s) of interest with other company 14 (7)
No conflicts of interest 21 (11)
CRO=contract research organisation.
* Some trials also had CRO employed co-authors.
† Refers to author employed by industry company other than industry 
funder and one author with unclear affiliation (CRO or private clinic).
‡ Those who had conflicts of interest with funder could also have 
conflicts of interest with other industry companies. Grant from funder or 
being investigator in included trial did not count as conflict of interest.
No
 o
f t
ria
ls
Design0
80
120
160
40
Funder only
Academic authors only
Funder and academic authors
Funder and CRO
Funder, academic authors, and CRO
Academic authors and CRO
Conduct Data analysis Reporting
Not mentioned
CRO only
fig 2 | reported involvement in 200 trials. crO=contract research organisation
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Discrepancies between survey information and 
publications
One responder reported that the funder was involved 
in the design, but this was not described in the 
publication. Ten responders (six from North America 
and four from Europe) acknowledged a drug regulatory 
agency as having the main decision power on choice of 
comparator and/or outcome and/or the final say on the 
trial design. However, the corresponding publications 
acknowledged regulator input in only two of the 10 
trials.
Four (5%) of the responders reporting funder 
involvement in the data analysis stated that the funder 
employee was not named in the trial publication. 
Three (4%) other responders reported that the funder 
was involved in data analysis, but this was not 
described at all in the trial publication. Four (5%) 
responders reported CRO involvement in data analysis, 
but the CRO employee who did the analysis was not 
named in the publication. Two (3%) other responders 
reported CRO involvement in data analysis, whereas 
the corresponding publications did not describe this 
involvement.
Fifty three (66%) responders reported that the 
manuscript was drafted solely by academic authors. 
However, 27 (51%) of these responders’ trials had 
writing assistance from a CRO according to the 
corresponding publication. Five (6%) responders 
reported that the manuscript was drafted by a funder 
or CRO employee who was not a co-author or a named 
contributor in the trial publication. One responder, 
who was last author of the publication, did not 
know who actually wrote the draft. One responder 
reported CRO involvement in reporting, whereas 
the corresponding publication did not describe this 
involvement. Fifty two (65%) responders reported that 
academic authors solely had final say on the published 
manuscript. However, 40 of these 52 trials included 
funder employed co-authors.
Ten (13%) responders described involvement of 
an unnamed funder, CRO employee, or both in the 
data analysis and/or reporting. An additional 7 (9%) 
responders described funder and/or CRO employee 
involvement in trial design, data analysis, or reporting 
that was not reported in the corresponding publication.
Trial agreements and data access
Sixty three (79%) responders reported signing a trial 
agreement with the funder (table 2). Eight of these 
commented that the contract they signed gave the funder 
the right to review and comment on the manuscript 
and presentations but did not give the funder approval 
rights. However, six of these responders’ eight trials 
had funder employed co-authors, thereby indirectly 
giving funder approval right (appendices 6 and 7), 
and one of these authors also described disagreements 
with the funder about the content of the manuscript. 
Only 4 (6%) of the 63 trials with agreements had a 
description of a confidentiality agreement in the trial 
publication. Another trial publication reported that 
no confidentiality agreement existed, but the survey 
contradicted this and described that the data was 
100% embargoed before publication suggesting the 
existence of a confidentiality agreement.
Most of the lead academic authors reported access to 
the entire dataset (table 2). Seventy three of the trials 
allowed for a comparison of access to data between 
survey responses and statements in trial publications. 
In 5 (7%) trials, the lead academic author had access 
to data according to the publication, but they denied 
such access in the survey. In three trial publications 
that used the phrase “The authors vouch for the data,” 
the lead academic author did not have access to the 
data according to the survey.
Experience with collaboration
Only a few responders reported problems with the 
funder, and the most common problems were delays 
in publication and disagreements with the funder, 
mostly concerning trial design and reporting (table 2). 
Disagreements were generally described as minor (see 
box 1 and appendix 6 for detailed comments).
The most commonly reported benefit of 
collaborating with the industry funder was funding, 
reported by 33 (41%) responders. Thirteen (16%) 
responders found the fact that they were contributing 
new research a benefit of the collaboration. Eight 
(10%) responders reported the trial publication and 
subsequent publications using the same dataset as a 
benefit of the collaboration (box 1 and appendix 6). In 
our subgroup analyses, we did not find any differences 
in characteristics of trials or responses to the survey in 
relation to conflicts of interest, type of intervention, 
industry involvement, and collaboration status 
(appendix 7).
discussion
We found that the funders of industry funded trials were 
usually involved in every step of the trial. Nevertheless, 
No
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ls
Choice of
comparator
0
30
45
60
15
Funder only*
Academic authors only
Collaboration†
Academic authors and regulator collaboration
Other‡
Funder and regulator collaboration
Choice of
outcomes
Final say
on design
Draed
manuscript
Final say on
published
manuscript
Do not know/not available
fig 3 | reported involvement according to survey. crO=contract research organisation. 
*funder and crO also includes unacknowledged people for conducted statistical analysis 
and drafting of manuscript. †collaboration includes academic, funder, and/or crO; 
academic, funder, and/or regulator; academic and crO; funder and crO. ‡Other includes 
regulator, journal, unknown, or unclear. no responders reported crO as the only actor for 
any category
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the role of academic authors, funders, and CROs 
varied greatly. Generally, both academic authors and 
funders were involved in the trial design, conduct, 
and reporting. However, the actual data analysis was 
most often done by funder or CRO employees. Our 
study showed inaccuracy of published descriptions of 
authors’ roles and access to data. Few industry funded 
trials were completely independently conducted by 
academics, and sometimes industry involvement 
was downplayed or omitted in trial publications. The 
lead academic authors often found the collaboration 
beneficial, particularly in relation to funding of the 
trial. However, some academic authors reported 
disagreements with the funder, mostly concerning trial 
design and reporting.
context of findings
Lundh et al analysed trials published in the Lancet 
in 2008-9 and had access to trial protocols.12 Our 
findings of extensive involvement of industry funders 
and that the roles of funders and CROs were sometimes 
downplayed in the trial publications are similar to 
the findings of Lundh et al. Data are often stored and 
owned by the industry funder; similarly to Lundh et 
al, we found that trial publications rarely described 
what type of data the academic authors had access 
to and whether they used this access.18 19 We believe 
that descriptions of data access in publications may 
not be accurate. In 67 of the 69 Lancet protocols, no 
information was given on academic authors’ access to 
data, in striking contrast to the papers, which indicated 
that one or more academic authors had access to the 
data in 64 trials.12
Ghost authorship, whereby people are involved 
in important aspects of clinical trials without the 
involvement being disclosed in the publications, has 
been well described.4  10  20  21 We found evidence of 
ghost authorship in 17 of 80 trials, but this is likely to 
be an underestimate as some lead academic authors 
had a small role in the conduct, analysis, and reporting 
of the trial. Thus, “ghost authoring” could have taken 
place without the lead academic authors being aware. 
Gøtzsche et al found a much higher prevalence 
of 75% of ghost authorship in trials, particular in 
box 1: selected comments in response to survey questions
Selected comments for benefits of collaborating with the trial industry funder
Publication—“The Journal X paper! And more to come”; “Opportunity to author papers of important study results in high impact journals”
Personal benefits—“Being PI of a positive trial is always a benefit in CV and recognition”; “…That being said, I would not object to all industry-sponsored studies 
being listed as ‘the Trial X Investigators’ or something similar—ultimately, despite our input, these are studies done by the company”
Selected comments for confidentiality agreement
Confidential until publication—“No for results which are already in the public domain, obviously, but yes for all other unpublished data”
Miscellaneous—“The agreement stated that sponsor could request up to 30 days confidentiality if necessary for patent protection”
Selected comments for choice of comparator
Collaboration—“The company has to obviously agree with the study design. They fund the trial”
Miscellaneous—“The sponsor did not want a placebo arm in the trial. We insisted upon it for safety evaluation and they ultimately agreed to a placebo arm with 
deferred treatment”
Selected comments for final say in study design
Funder—“We advised the sponsor study team (extensively) and I would generally say that they listened, but they did not ‘require’ sign-off from the steering 
committee before finalizing the protocol so in that sense, they had final say”
Selected comments for statistical analysis
Miscellaneous—“We analyse with independent academic and with the funder statisticians. Sometimes we have to rely on only the funder statisticians which is 
less satisfactory. However SAPs and protocols are submitted to regulatory and editors before analysis and publication”
Selected comments for access to data
Miscellaneous—“Not the ENTIRE dataset, but much of it and we were encouraged to ask for specific analyses”; “I had access to all the data but did not have access 
to the database. E.g., all analyses conducted in sponsor’s dataset. Any analysis that we wanted was done”
Selected comments for using data access
Miscellaneous—“I anticipate some 30 high-quality papers will be published using this data set. 12 already published, 4 submitted and 10 currently in 
preparation”
Selected comments for drafting the manuscript
Academics writing intro and discussion—“I drafted the introduction and discussion sections, while the company scientific writers drafted the methodology and 
results sections”
Selected comments for how disagreements with funder were handled by the funder
Miscellaneous—“Want to postpone and change the wording”
Selected comments from additional comments
Miscellaneous—“Further report not approvable or not approved by the sponsor”
Typos have been corrected. Comments from different authors are separated by “”;. Words have been replaced by pseudonyms to ensure the anonymity of the author.
 o
n
 12 June 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3654 on 3 October 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;363:k3654 | doi: 10.1136/bmj.k3654 7
relation to data analysis.20 However, prevalence of 
ghost authorship may have diminished over time, as 
we found that 87% of trials had industry co-authors 
compared with 64% in the study by Gøtzsche et al.20 
The ICMJE recommends that those who do not fulfil the 
authorship criteria but have contributed to the study 
or publication are acknowledged in the publication.15 
Therefore, the 17 trials identified from the survey in 
which people contributed to the statistical analysis or 
writing of the manuscript were in direct breach of the 
ICMJE recommendations by not listing them as authors 
or contributors in the trial publication.
Some academic authors reported that having a high 
impact publication was a benefit of the collaboration, 
and academic authors were often (96%) prominently 
placed as corresponding authors. Apart from the 
financial gain from industry collaboration, our results 
suggest that the collaboration may also lead to non-
financial or indirect financial gain for academic 
authors—for example, through authorship of a paper 
in a high impact journal and authorship of subsequent 
secondary publications thereby influencing tenure, 
salary, and grant applications.22 Future studies should 
quantify the magnitude of this type of conflict of 
interest.
strengths and weaknesses of study
To our knowledge, this is the first study to directly 
survey a large cohort of international academic 
authors involved in industry funded trials published 
in high impact general medical journals. Furthermore, 
no studies have obtained and analysed the input of 
academic authors regarding their experience with 
industry funded trials, so this study provides novel 
insights. Our use of data from both trial publications 
and survey responses allowed us more comprehensive 
data compared with studies solely based on a single 
information source.8  10 A major strength of our study 
is the fact that we included trials from all over the 
world, so our results are applicable at an international 
level. Furthermore, the format of the survey, whereby 
individual authors could not be identified by the 
public, is likely to have provided us with more truthful 
responses, especially with regard to sensitive topics.
Our findings may be somewhat limited by the 
retrospective nature of the survey. However, we 
included only the most recent trials, so the authors 
are more likely to remember the details compared with 
studies focusing on the past experience of academics 
in general.10 Another possible limitation is the mixture 
of industry funded trials initiated by academics and 
company trials initiated for regulatory purposes. 
From trial publications, we could not completely 
distinguish between these types of trials, and funder 
involvement is likely more pronounced in industry 
funded trials conducted for regulatory purposes. We 
included trials from high impact journals, of which 
most were published in the NEJM and Lancet. Thus, 
the generalisability to smaller journals and specialty 
journals could be limited. Furthermore, our prevalence 
of conflicts of interest is likely to be a conservative 
estimate as it was based on disclosures in journals. 
Previous studies have found that such conflicts are often 
under-reported in publications, so the actual figures 
may be even higher.22-24 Additionally, we assessed the 
supplementary material only for trials published in the 
NEJM. Academic authors with industry ties are more 
likely to be favourable towards industry involvement in 
research than those without ties, so our survey results 
may show this bias.25 Although our survey of academic 
authors gave valuable insights into the benefits and 
problems related to industry-academic collaboration, 
future research could consider taking a more 
qualitative approach to gain additional understanding 
of the motives of academic authors. Finally, despite 
many reminders we received survey responses from 
only 80 (40%) academic authors, which was somewhat 
lower than previous surveys of academic authors.10 18 
However, we dealt with a sensitive topic and surveyed 
academics who are quite busy. Previous studies on 
sensitive topics have found response rates lower than 
or comparable to ours.26-28 The non-responders who 
declined via email primarily declined owing to lack of 
time or lack of interest in participating. Furthermore, 
the characteristics of trials and authors did not differ 
between responders and non-responders, suggesting 
that the included responses were representative of the 
overall group of included academic authors.
Meaning of findings
We found room for more accurate reporting of authors’ 
contribution in industry funded trials published in 
high impact general medical journals. A solution 
could be that guidelines such as ICMJE and CONSORT 
specifically require authors and funders to report their 
involvement in key trial components, particularly 
related to analysis and ownership of and access to 
data.15  29 To improve the accuracy of disclosures of 
funders’ contributions, the disclosure should name 
everyone conducting the statistical analysis and their 
affiliation, as well as discriminate between those who did 
the actual analysis and those who merely participated 
table 2 | survey reported experience among lead academic authors (n=80)*. values are 
numbers (percentages)
yes no
Do not know or 
not available
trial agreement
Signed trial agreement with industry funder 63 (79) 16 (20) 1 (1)
Signed trial agreement included publication agreement† 46 (73) 12 (19) 5 (8)
Signed trial agreement included presentation agreement† 33 (52) 21 (33) 9 (14)
Signed trial agreement included confidentiality agreement† 39 (62) 19 (30) 5 (8)
Data access
Had access to entire trial dataset 63 (79) 9 (11) 8 (10)
Access used by those with access to entire data‡ 56 (89) 6 (10) 1 (2)
Problems
Delay in publication due to funder 3 (4) 70 (88) 7 (9)
Disagreements with funder 9 (11) 64 (80) 7 (9)
collaboration
Already collaborating with funder/would in future 67 (84) 1 (1) 12 (15)
* 7 authors provided responses to only some of the questions.
† n=63; question was available only to those who answered yes to signing agreement with industry funder.
‡ n=63; question was available only to those who answered yes to data access.
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in data acquisition and interpretation. In addition, 
publications should provide precise information about 
who holds and owns the entire dataset as well as 
who had access to it. Furthermore, ethics committees 
should review complete descriptions of the roles of 
funders and academic authors and consider them 
in their deliberations. More accurate reporting of 
contributorship should give patients greater confidence 
in trial results and conclusions. Furthermore, journals 
could refuse publication when these elements are not 
clearly reported. The presence of ghost authorship 
could perhaps be reduced by asking the authors to 
confirm and sign a statement that all contributors to 
their study have been acknowledged and correcting 
papers with evidence of ghost authorship. Journals 
could also penalise all authors of ghost written papers 
by banning them from future publication. Trials from 
high impact journals have important effect on clinical 
decisions.30 31 Nevertheless, only a few of our included 
trials had independent analysis. However, academics 
can demand control over design, data storage, and 
full data ownership, analysis, and reporting, thereby 
improving independence and greater reliability of trial 
results.
conclusions
Industry employees and academic authors are involved 
in the design, conduct, and reporting of most industry 
funded trials in high impact journals. However, the 
data analysis was often conducted without academic 
involvement. Academics view the collaboration with 
the industry funder as beneficial, but some report loss 
of academic freedom.
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